Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of “Buy” from Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given a consensus rating of “Buy” by the seven research firms that are covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $61.33.

A number of analysts have commented on the company. Canaccord Genuity Group assumed coverage on Arcturus Therapeutics in a research report on Wednesday, December 13th. They issued a “buy” rating and a $90.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Canaccord Genuity Group initiated coverage on Arcturus Therapeutics in a report on Wednesday, December 13th. They issued a “buy” rating for the company. Citigroup boosted their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th.

Insider Buying and Selling at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.80% of the company’s stock.

Institutional Trading of Arcturus Therapeutics

Large investors have recently bought and sold shares of the company. State Street Corp raised its stake in shares of Arcturus Therapeutics by 56.5% during the 1st quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company’s stock valued at $86,756,000 after purchasing an additional 1,161,883 shares during the period. Bank of America Corp DE raised its position in shares of Arcturus Therapeutics by 535.2% in the fourth quarter. Bank of America Corp DE now owns 685,954 shares of the biotechnology company’s stock worth $11,634,000 after buying an additional 577,968 shares in the last quarter. Balyasny Asset Management LLC boosted its stake in Arcturus Therapeutics by 3,039.8% during the third quarter. Balyasny Asset Management LLC now owns 339,383 shares of the biotechnology company’s stock valued at $5,030,000 after buying an additional 328,574 shares during the period. Renaissance Technologies LLC purchased a new position in Arcturus Therapeutics during the second quarter worth about $7,620,000. Finally, Woodline Partners LP raised its holdings in shares of Arcturus Therapeutics by 30.7% in the 2nd quarter. Woodline Partners LP now owns 1,069,814 shares of the biotechnology company’s stock valued at $30,682,000 after acquiring an additional 251,376 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ:ARCT opened at $33.77 on Monday. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $43.81. The company has a market cap of $908.92 million, a P/E ratio of -32.47 and a beta of 2.64. The stock’s 50-day moving average is $36.21 and its 200-day moving average is $29.40.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.